Mayo Clinic Laboratory and Pathology Research Roundup: Feb. 1

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Study of the Week

Mayo Clinic Researchers Reveal Seasonal Pattern of Bordetella pertussis in U.S.

PatelBordetella pertussis is the highly contagious etiological agent of pertussis (a.k.a., whooping cough). While there are several types of laboratory tests used for B. pertussis, Mayo Medical Laboratories offers a PCR assay. In a recent issue of the Journal of the Pediatric Infectious Diseases Society, Mayo Clinic researchers, first author Robin Patel, M.D., Chair of the Division of Clinical Microbiology, report on an eight-year review of its PCR assay testing that revealed jointed testing patterns compared to positivity rates.

Featured Abstracts

Updated TDP-43 in Alzheimer's Disease Staging Scheme

person-with-old-photographs-and-memories-16x9In a new study published in the journal Acta Neuropathologica, Mayo Clinic researchers updated the TDP-43 in Alzheimer's disease staging scheme by assessing the topography of TDP-43 in 193 cases of Alzheimer's disease, and in 14 different brain regions. The updated staging scheme is superior to previous staging scheme, classifying 100% of the cases versus 94% in the old scheme, based on criteria provided, and shows clinical significance with some regions and with increasing stage.

Comparative Effects of Biologics on Cardiovascular Risk Among Older Patients With Rheumatoid Arthritis

close-up-of-hands-with-rheumatoid-arthritis-16x9Mayo Clinic researchers conducted a study, published in the Annals of the Rheumatic Diseases journal, to compare the coronary heart disease risk among patients with rheumatoid arthritis initiating common biologic disease-modifying antirheumatic drugs of different mechanisms. In the study, researchers compared the incidence rates of acute myocardial infarction (AMI) and a composite outcome of AMI or coronary revascularisation, and used multivariable adjusted Cox regression models to examine the associations between the type of biologic and the two outcomes. Findings from this observational study of patients with RA suggested that antitumour necrosis factor biologics may be associated with higher AMI risk compared with abatacept initiators.

Validation of the Revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic Patients

cardio-960x540The primary objective of treatment in essential thrombocythemia (ET) is to prevent thromboembolic complications. The International Prognostic Score of Thrombosis for ET (IPSET-thrombosis) has been established to identify "low", "intermediate", and "high" risk patients. IPSET-thrombosis was recently revised to quantify the additional pro-thrombotic effect of JAK2V617F and cardiovascular risk factors in specific risk subcategories. In a current study published in the American Journal of Hematology, Mayo Clinic researchers analyzed 585 patients with ET to validate the revised IPSET-thrombosis by confirming significant differences in thrombosis risk between "very low" and "low" and between "intermediate" and "high". Based on their findings, the revised IPSET-thrombosis needs confirmation in prospective studies, especially in terms of risk-adapted therapy that includes the need for aspirin therapy in very low risk, twice-daily aspirin therapy for low risk and cytoreductive therapy for low or intermediate risk patients.

Published to PubMed This Week

Kelley Luedke

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.